The Official Journal of Skin and Stem Cell Research Center
Image Credit: J Skin Stem Cell
Facial Ulcer: A Harbinger of Post-COVID-19 Mucormycosis, a Case Report
Authors
Abstract
Facial ulcers may be the manifestation of a wide variety of disorders with infective, inflammatory, granulomatous, or malignant etiopathogenesis, leading to challenges in differential diagnosis and management. Mucormycosis is an angio-invasive, rapidly spreading, and potentially fatal fungal infection beginning from the nose and paranasal sinuses after the inhalation of fungal spores, manifesting with cutaneous necrotic eschar. The rhinomaxillary region is the commonest site involved, particularly in immunocompromised individuals. Mucormycosis incidence in people with coronavirus disease 2019 (COVID-19) is on the rise, especially in India during the second wave. Diabetes mellitus is an independent risk factor for severe COVID-19 infection, as well as for mucormycosis. We report an elderly gentleman with uncontrolled diabetes, treated for the COVID-19 infection, who presented with an ulcer over the left nasal ala. This case report highlights the importance of high-index suspicion and prompt and aggressive multidisciplinary management of mucormycosis, as a life-saving measure.
Highlights
Footnotes
Authors' Contribution: Study concept and design: V. B. and R. C.; Analysis and interpretation of data: V. B. and J. A.; Drafting the manuscript: J. A.; Critical revision of the manuscript for important intellectual content: V. B, N. B., and R. C.; Statistical analysis: V. B. and J. A.
Conflict of Interests: The authors declare no conflict of interest.
Funding/Support: There was no funding support.
Informed Consent: Informed consent was taken.
References
- 1.Kubin CJ, McConville TH, Dietz D, Zucker J, May M, Nelson B, et al. Characterization of bacterial and fungal infections in hospitalized patients with coronavirus disease 2019 and factors associated with health care-associated infections. Open Forum Infect Dis. 2021;8(6):ofab201. [PubMed ID: 34099978]. [PubMed Central ID: PMC8135866]. https://doi.org/10.1093/ofid/ofab201.
- 2.Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses. 2001;44(7-8):253-60. [PubMed ID: 11714058].
- 3.Sugar AM. Mandell G, Bennett J, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. New York, USA: Churchill Livingstone; 2000.
- 4.Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel). 2020;6(4). [PubMed ID: 33147877]. [PubMed Central ID: PMC7711598]. https://doi.org/10.3390/jof6040265.
- 5.Chander J, Kaur M, Singla N, Punia RPS, Singhal SK, Attri AK, et al. Mucormycosis: Battle with the deadly enemy over a five-year period in India. J Fungi (Basel). 2018;4(2). [PubMed ID: 29642408]. [PubMed Central ID: PMC6023269]. https://doi.org/10.3390/jof4020046.
- 6.Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1). [PubMed ID: 30901907]. [PubMed Central ID: PMC6462913]. https://doi.org/10.3390/jof5010026.
- 7.Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264 e5-8. [PubMed ID: 32972795]. [PubMed Central ID: PMC7493738]. https://doi.org/10.1016/j.ajem.2020.09.032.
- 8.Deutsch PG, Whittaker J, Prasad S. Invasive and non-Invasive fungal rhinosinusitis-A review and update of the evidence. Medicina (Kaunas). 2019;55(7). [PubMed ID: 31261788]. [PubMed Central ID: PMC6681352]. https://doi.org/10.3390/medicina55070319.
- 9.Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24(2):247-80. [PubMed ID: 21482725]. [PubMed Central ID: PMC3122495]. https://doi.org/10.1128/CMR.00053-10.
Copyright
Copyright © 2021, Journal of Skin and Stem Cell. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Similar Articles
Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation
Ghazizadeh M, Mohseni M, Asadi M, Hoseini A. Mucormycosis Following COVID-19: A Comprehensive Case Series Investigation. Arch Clin Infect Dis. 2024;19(2):e141644. doi: https://doi.org/10.5812/archcid-141644
Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the COVID-19 Area: A Consensus of Iranian Experts
Pakdel F, Mardani M, Salehi M, Khodavaisy S, Tabari A, et al. Practice Guideline on Prevention, Diagnosis, and Treatment of Rhino-Orbito-Cerebral Mucormycosis in the COVID-19 Area: A Consensus of Iranian Experts. Arch Clin Infect Dis. 2022;17(4):e127072. doi: https://doi.org/10.5812/archcid-127072
Anesthetic Management of COVID-19 Associated Mucormycosis: A Narrative Review
Singh A, Ankalagi B, Khanna P. Anesthetic Management of COVID-19 Associated Mucormycosis: A Narrative Review. J Cell Mol Anesth. 2021;6(4):e149736. doi: https://doi.org/10.22037/jcma.v6i4.35302
Risk Factors for Mucormycosis in COVID-19 Patients
Taghinejad Z, Asgharzadeh M, Asgharzadeh V, Kazemi A. Risk Factors for Mucormycosis in COVID-19 Patients. Jundishapur J Microbiol. 2021;14(8):e117435. doi: https://doi.org/10.5812/jjm.117435
COVID-19 Associated Mucormycosis and Risk Factors: A Case-Control Study from Turkey
Kılınç Toker A, Turunc Ozdemir A, Kanat A, Eryilmaz Eren E, Sav H, et al. COVID-19 Associated Mucormycosis and Risk Factors: A Case-Control Study from Turkey. Jundishapur J Microbiol. 2024;17(4):e146817. doi: https://doi.org/10.5812/jjm-146817
- Scopus by DOI: 0
Last Update: 1 week ago
- Scopus by Title: 0
Last Update: 1 week ago
- Scopus by Title (Ref): 1
Last Update: 1 week ago
- CrossRef: 0
Last Update: 5 days ago




